HUYA Bioscience International

OverviewSuggest Edit

HUYA Bioscience International is a company specializing in the biopharmaceutical products. It provides a number of compounds including the oncology drug HBI-8000, the anti-arrhythmic HBI-3000, and the small molecule with regenerative properties for myocardial infarction HBI-3802.
TypePrivate
Founded2004
Websitehuyabio.com

Latest Updates

Employees (est.) (Mar 2020)74

Key People/Management at HUYA Bioscience International

Mireille Gillings

Mireille Gillings

President and CEO
Suzanne Romano

Suzanne Romano

Chief Administrative Officer
Clement Gingras

Clement Gingras

COO China & CTO
Show more

HUYA Bioscience International Financials and Metrics

Summary Metrics

Founding Date

2004

HUYA Bioscience International total Funding

$7.6 m

HUYA Bioscience International latest funding size

$48 m
HUYA Bioscience International's latest funding round in April 2015 was reported to be $48 m. In total, HUYA Bioscience International has raised $7.6 m
Show all financial metrics

HUYA Bioscience International Online and Social Media Presence

Embed Graph

HUYA Bioscience International Frequently Asked Questions

  • When was HUYA Bioscience International founded?

    HUYA Bioscience International was founded in 2004.

  • Who are HUYA Bioscience International key executives?

    HUYA Bioscience International's key executives are Mireille Gillings, Suzanne Romano and Clement Gingras.

  • How many employees does HUYA Bioscience International have?

    HUYA Bioscience International has 78 employees.

  • Who are HUYA Bioscience International competitors?

    Competitors of HUYA Bioscience International include Mirati Therapeutics, Karyopharm Therapeutics and Northwest Biotherapeutics.